SCHEMBL20719275

SCHEMBL20719275

Cn1cnc2c[c]cc(Cl)c21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 12/20 0.40
DPP8 Q6V1X1 5/20 0.40
GDA Q9Y2T3 2/20 0.33
KDM4E B2RXH2 1/20 0.31
PIK3CD O00329 1/20 0.31
POLB P06746 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
CNR1 P21554 1/20 0.31
ACHE P22303 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31
ADORA1 P30542 1/20 0.31
NTSR1 P30989 1/20 0.31
MC3R P41968 1/20 0.31
NOTUM Q6P988 1/20 0.31
SIRT3 Q9NTG7 1/20 0.31
NR2E1 Q9Y466 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21187468 0.74 DPP4 (0.51) DPP4DPP8NPC1RAB9A
SCHEMBL10673703 0.69 DPP4 (0.49) DPP4DPP8GDAPIK3CDPOLB
SCHEMBL16617958 0.68 DPP4 (0.45) DPP4DPP8GDAKDM4ENPC1
SCHEMBL29393193 0.67 DPP4 (0.41) DPP4DPP8GDAKDM4EPIK3CD
SCHEMBL26796169 0.66 DPP4 (0.38) DPP4DPP8GDAPIK3CDPOLB
SCHEMBL23208864 0.64 DPP4 (0.42) DPP4DPP8NPC1RAB9A
SCHEMBL21187465 0.64 DPP4 (0.45) DPP4DPP8
SCHEMBL2067210 0.64 GRM5 (0.38) ADORA2AADORA1
SCHEMBL1418905 0.63 GRM5 (0.40) KDM4EPOLBNPC1RAB9A
SCHEMBL16597631 0.63 GRM2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2020-03-17 US claimed
US-20190047959-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US claimed
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2020-03-17 US disclosed
US-10399944-B2 Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-09-03 US disclosed
US-10336701-B2 Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-07-02 US disclosed
US-20190047959-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US disclosed
US-20190047961-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US disclosed
US-20190047960-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336701-B2 Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 DPP4 1288/4885DPP8 1845/4885GDA 3353/4885
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 DPP4 1302/4885DPP8 1833/4885GDA 3305/4885
US-20190047960-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, PTGER1, PTGER2 DPP4 1288/4885DPP8 1845/4885GDA 3353/4885
US-20190047959-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, PTGER1, PTGER2 DPP4 1302/4885DPP8 1833/4885GDA 3305/4885
US-10399944-B2 Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 DPP4 1264/4885DPP8 1843/4885GDA 3333/4885
US-20190047961-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, PTGER1, PTGER2 DPP4 1264/4885DPP8 1843/4885GDA 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.